NDA 212950 · Viiv Hlthcare
Rukobia
Fostemsavir Tromethamine · Oral
NovelBreakthrough therapyPriority reviewLast checked: Nov 19, 2026Latest source record: Feb 13, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
Jul 2, 2020
Approved uses
2
Original approval plus efficacy supplements
Registered trials
0
0 Phase 3, 0 recruiting
FAERS reports
243
77 serious, 19 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Feb 13, 2024.
RUKOBIA, in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen due to resistance, intolerance, or safety considerations [see Clinical Studies ( 14 )]. RUKOBIA, a human immunodeficiency virus type 1 (HIV-1) gp120-directed attachment inhibitor, in combination with other antiretroviral(s), is indicated for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen due to resistance, intolerance, or safety considerations. ( 1 , 12.4 )
Mechanism: RUKOBIA is an HIV-1 antiretroviral agent [see Microbiology ( 12.4 )].
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 24, 2022 Supplement 2 · Efficacy
- Jul 2, 2020 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyLabelLetterReview
1 products under this application
- RUKOBIA · FOSTEMSAVIR TROMETHAMINE EQ 600MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Fostemsavir Tromethamine" as an intervention, any sponsor and status, largest first.
No registered drug trials name this ingredient.
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use30
- nausea17
- death16
- product dose omission issue15
- drug ineffective14
- viral load increased12
- rash11
- dizziness10
- fatigue10
- pathogen resistance10
- product residue present9
- virologic failure9
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2020 | 10 |
| 2021 | 28 |
| 2022 | 46 |
| 2023 | 52 |
| 2024 | 38 |
| 2025 | 46 |
| 2026 | 23 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Rukobia (Fostemsavir Tromethamine)
2024 spending
$115M
Beneficiaries
1,505
12,716 claims
Per beneficiary
$76,437
$147.93 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $6,695,198 |
| 2021 | $38,947,235 |
| 2022 | $63,858,997 |
| 2023 | $91,208,742 |
| 2024 | $115,037,191 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: GSK
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.